Recursion(US:RXRX) ZACKSยท2025-07-03 22:51Company Performance - Recursion Pharmaceuticals (RXRX) closed at $5.27, reflecting a +1.15% change from the previous day, outperforming the S&P 500's daily gain of 0.83% [1] - Over the last month, the company's shares increased by 6.11%, exceeding the Medical sector's gain of 2.2% and the S&P 500's gain of 4.99% [1] Upcoming Earnings - The upcoming earnings release is projected to report earnings of -$0.34 per share, indicating a year-over-year growth of 15% [2] - Revenue is estimated at $15.58 million, representing an 8.02% increase from the prior-year quarter [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of -$1.34 per share and revenue of $74.95 million, reflecting shifts of +20.71% and +27.38% respectively from the last year [3] - Recent adjustments to analyst estimates indicate evolving short-term business trends, with positive revisions suggesting analyst optimism about the company's profitability [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] - Recursion Pharmaceuticals currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 0.19% higher over the past month [5] Industry Context - The Medical - Biomedical and Genetics industry is part of the Medical sector and currently holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [6] - Strong individual industry groups, as measured by the Zacks Industry Rank, show that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]